Literature DB >> 22972305

Cellular prion protein accelerates colorectal cancer metastasis via the Fyn-SP1-SATB1 axis.

Qianwei Wang1, Jianming Qian, Fangrui Wang, Zhenyu Ma.   

Abstract

The cellular prion protein (PrPc) is a glycoprotein anchored by glycosylphosphatidylinositol to the cell surface and is abundantly expressed in various tissues. The putative roles of PrPc are thought to be related to cell signaling, survival, and differentiation and cancer progression. In this study, we demonstrated that the expression of PrPc correlates with a more aggressive and histologically unfavorable disease in colorectal carcinomas. Moreover, we found that PrPc mediates the process of epithelial-mesenchymal transition and, thereby, promotes CRC metastasis. Transcriptome profiling of PrPc-depleted cells revealed downregulation of the special AT-rich sequence-binding protein-1 (SATB1). PrPc is demonstrated to be involved in regulating SATB1 expression via the Fyn-SP1 pathway. Since SATB1 has been previously proposed as a key protein that controls tumor development and progression, knockdown of PrPc resulted in a reduced metastatic capacity in CRC cells, as well as a reduction in distant metastases in vivo. In conclusion, our data characterize a novel molecular mechanism that links PrPc expression to the regulation of CRC metastasis. Targeting PrPc will, therefore, be a promising strategy to overcome the metastatic advantage in colorectal tumors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22972305     DOI: 10.3892/or.2012.2025

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  20 in total

1.  Role of HSPA1L as a cellular prion protein stabilizer in tumor progression via HIF-1α/GP78 axis.

Authors:  J H Lee; Y-S Han; Y M Yoon; C W Yun; S P Yun; S M Kim; H Y Kwon; D Jeong; M J Baek; H J Lee; S-J Lee; H J Han; S H Lee
Journal:  Oncogene       Date:  2017-07-31       Impact factor: 9.867

Review 2.  Targeting prion protein interactions in cancer.

Authors:  Tiago G Santos; Marilene H Lopes; Vilma R Martins
Journal:  Prion       Date:  2015       Impact factor: 3.931

3.  Cellular prion protein contributes to LS 174T colon cancer cell carcinogenesis by increasing invasiveness and resistance against doxorubicin-induced apoptosis.

Authors:  Cornelius Kwang-Lee Chieng; Yee-How Say
Journal:  Tumour Biol       Date:  2015-05-17

Review 4.  SATB1 and 2 in colorectal cancer.

Authors:  Jason Brocato; Max Costa
Journal:  Carcinogenesis       Date:  2014-12-27       Impact factor: 4.944

5.  Sp1 is overexpressed and associated with progression and poor prognosis in bladder urothelial carcinoma patients.

Authors:  Jialiang Zhu; Ziwen Lu; Mang Ke; Xianguo Cai
Journal:  Int Urol Nephrol       Date:  2022-04-25       Impact factor: 2.370

Review 6.  Prion protein scrapie and the normal cellular prion protein.

Authors:  Caroline J Atkinson; Kai Zhang; Alan L Munn; Adrian Wiegmans; Ming Q Wei
Journal:  Prion       Date:  2016       Impact factor: 3.931

7.  Prion protein binding to HOP modulates the migration and invasion of colorectal cancer cells.

Authors:  Tonielli Cristina Sousa de Lacerda; Bruno Costa-Silva; Fernanda Salgueiredo Giudice; Marcos Vinicios Salles Dias; Gabriela Pintar de Oliveira; Bianca Luise Teixeira; Tiago Goss Dos Santos; Vilma Regina Martins
Journal:  Clin Exp Metastasis       Date:  2016-04-25       Impact factor: 5.150

8.  Fyn knockdown inhibits migration and invasion in cholangiocarcinoma through the activated AMPK/mTOR signaling pathway.

Authors:  Shao-Cheng Lyu; Dong-Dong Han; Xian-Liang Li; Jun Ma; Qiao Wu; Hong-Meng Dong; Chun Bai; Qiang He
Journal:  Oncol Lett       Date:  2017-12-07       Impact factor: 2.967

9.  Expression analysis of genes and pathways associated with liver metastases of the uveal melanoma.

Authors:  Yuanyuan Zhang; Yong Yang; Lei Chen; Jianhong Zhang
Journal:  BMC Med Genet       Date:  2014-03-05       Impact factor: 2.103

Review 10.  Prognostic significance of SATB1 in gastrointestinal cancer: a meta-analysis and literature review.

Authors:  Sheng Zhang; Yi Xin Tong; Xiang Shang Xu; Hui Lin; Teng Fei Chao
Journal:  Oncotarget       Date:  2017-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.